International Ophthalmology

, Volume 39, Issue 11, pp 2637–2648 | Cite as

Genetic polymorphisms associated with the prevalence of retinal vein occlusion in a Greek population

  • Aikaterini Christodoulou
  • Eleni Bagli
  • Maria Gazouli
  • Marilita M. Moschos
  • Georgios KitsosEmail author
Original Paper



To investigate possible associations of single-nucleotide polymorphisms (SNPs) from five genes with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).


A total of 69 patients with retinal vein occlusion-RVO (24 with BRVO and 45 with CRVO), and 82 controls, were enrolled in this study. All subjects were screened for hypertension, diabetes mellitus, hyperlipidemia, glaucoma, anticoagulant medication, smoking status and history of stroke. The genotyping of AGTR1-A1166C, adiponectin + 276 G/T, MMP2-1306C/T, Gpla/lla-C807T/G873A and VKORC1-G1639A polymorphisms was performed using restriction fragment length polymorphism or allele-specific polymerase chain reaction.


The percentage of the AGTR1-A1166C C allele carriers and Gpla/lla-C807T/G873A T/A carriers was significantly higher in the CRVO patients than in the controls (P = 0.00001 and P = 0.0004, respectively). At the multiple logistic regression analysis, the AGTR1-A1166C C allele carrier status and the Gpla/lla-C807T/G873A T/A allele carrier status were found to be associated with an increased risk of CRVO. Moreover, adiponectin + 276 G/T T allele carriers had a significantly increased risk of RVO in subjects ≥ 75 years old. There was no significant difference between the BRVO patients and controls concerning the genotype or the allele frequency distributions of these SNPs. The genotype distributions or allelic frequencies of the other evaluated polymorphisms did not significantly differ between the patients with RVO and the control subjects.


AGTR1 A1166C and Gpla/lla C807T/G873A polymorphisms are likely to be risk factors for CRVO. Adiponectin + 276 G/T SNP is likely to predispose to RVO in older subjects.


AGTR1 Adiponectin GpIa/IIa MMP2 RVO VKORC1 


Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10792_2019_1113_MOESM1_ESM.pdf (296 kb)
T/A allele carriers regarding Gpla/lla C807T/G873A polymorphism and C allele carriers regarding AGTR1 A1166C polymorphism, who are <75y/o, are at high risk of RVO. (PDF 296 kb)


  1. 1.
    Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124(5):726–732. CrossRefPubMedGoogle Scholar
  2. 2.
    Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33(2):111–131. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ehlers JP, Fekrat S (2011) Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 56(4):281–299. CrossRefPubMedGoogle Scholar
  4. 4.
    Hayreh SS (1994) Retinal vein occlusion. Indian J Ophthalmol 42(3):109–132PubMedGoogle Scholar
  5. 5.
    Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D (1982) Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 100(7):1132–1140CrossRefGoogle Scholar
  6. 6.
    Rosendaal FR, Reitsma PH (2009) Genetics of venous thrombosis. Journal of thrombosis and haemostasis : JTH 7(Suppl 1):301–304. CrossRefPubMedGoogle Scholar
  7. 7.
    Russo PD, Damante G, Pasca S, Turello M, Barillari G (2015) Thrombophilic mutations as risk factor for retinal vein occlusion: a case-control study. Clin Appl Thromb Hemost 21(4):373–377. CrossRefPubMedGoogle Scholar
  8. 8.
    Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ (2005) Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 93(6):1021–1026. CrossRefPubMedGoogle Scholar
  9. 9.
    Demir S, Ortak H, Benli I, Alim S, Butun I, Gunes A, Ates O (2015) Genetic association between arterial stiffness-related gene polymorphisms in Brvo and Crvo patients in a Turkish population. Retina 35(10):2043–2051. CrossRefPubMedGoogle Scholar
  10. 10.
    Weger M, Steinbrugger I, Renner W, Poschl EM, Brockmann T, Rabensteiner DF, El-Shabrawi Y, Haas A (2013) Role of the vitamin K epoxide reductase complex subunit 1 (VKORC1)–1639G>A gene polymorphism in patients with retinal vein occlusion. Curr Eye Res 38(12):1278–1282. CrossRefPubMedGoogle Scholar
  11. 11.
    Ortak H, Demir S, Ates O, Sogut E, Alim S, Benli I (2013) Association of MMP2-1306C/T and TIMP2G-418C polymorphisms in retinal vein occlusion. Exp Eye Res 113:151–155. CrossRefPubMedGoogle Scholar
  12. 12.
    Weger M, Renner W, Steinbrugger I, Cichocki L, Temmel W, Stanger O, El-Shabrawi Y, Lechner H, Schmut O, Haas A (2005) Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophthalmology 112(11):1910–1915. CrossRefPubMedGoogle Scholar
  13. 13.
    Salomon O, Moisseiev J, Vilganski T, Dardik R, Kurtz S, Shpringer E, Steinberg DM, Rosenberg N (2006) Role of five platelet membrane glycoprotein polymorphisms in branch retinal vein occlusion. Blood Coag Fibrinol 17(6):485–488. CrossRefGoogle Scholar
  14. 14.
    Dodson PM, Haynes J, Starczynski J, Farmer J, Shigdar S, Fegan G, Johnson RJ, Fegan C (2003) The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion. Eye 17(6):772–777. CrossRefPubMedGoogle Scholar
  15. 15.
    Ortak H, Sogut E, Demir H, Ardagil A, Benli I, Sahin S (2012) Predictive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion. Clinical & experimental ophthalmology 40(7):743–748. CrossRefGoogle Scholar
  16. 16.
    Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6):540–545CrossRefGoogle Scholar
  17. 17.
    Silva GE, Vana KD, Goodwin JL, Sherrill DL, Quan SF (2011) Identification of patients with sleep disordered breathing: comparing the four-variable screening tool, STOP, STOP-Bang, and Epworth Sleepiness Scales. J Clin Sleep Med 7(5):467–472. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Singh A, Srivastava N, Amit S, Prasad SN, Misra MP, Ateeq B (2018) Association of AGTR1 (A1166C) and ACE (I/D) polymorphisms with breast cancer risk in North Indian population. Transl Oncol 11(2):233–242. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Fang WL, Zhou B, Wang YY, Chen Y, Zhang L (2010) Analysis of adiponectin gene polymorphisms in Chinese population with systemic lupus erythematosus. J Biomed Biotechnol 2010:401537. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ (2010) Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep 37(1):197–205. CrossRefPubMedGoogle Scholar
  21. 21.
    Dubovyk YI, Harbuzova VY, Ataman AV (2016) G-1639A but not C1173T VKORC1 gene polymorphism is related to ischemic stroke and its various risk factors in ukrainian population. Biomed Res Int 2016:1298198. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Jaulim A, Ahmed B, Khanam T, Chatziralli IP (2013) Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 33(5):901–910. CrossRefPubMedGoogle Scholar
  23. 23.
    Harsfalvi J, Stassen JM, Hoylaerts MF, Van Houtte E, Sawyer RT, Vermylen J, Deckmyn H (1995) Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood 85(3):705–711CrossRefGoogle Scholar
  24. 24.
    Kunicki TJ, Kritzik M, Annis DS, Nugent DJ (1997) Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 89(6):1939–1943CrossRefGoogle Scholar
  25. 25.
    Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ (1998) Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 92(7):2382–2388CrossRefGoogle Scholar
  26. 26.
    Brasier AR, Recinos A 3rd, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22(8):1257–1266CrossRefGoogle Scholar
  27. 27.
    Benigni A, Cassis P, Remuzzi G (2010) Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2(7):247–257. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp MA, Danser AH (1998) AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 32(5):825–830CrossRefGoogle Scholar
  29. 29.
    Takami S, Katsuya T, Rakugi H, Sato N, Nakata Y, Kamitani A, Miki T, Higaki J, Ogihara T (1998) Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension. Am J Hypertens 11(3 Pt 1):316–321CrossRefGoogle Scholar
  30. 30.
    Alavi-Shahri J, Behravan J, Hassany M, Tatari F, Kasaian J, Ganjali R, Tavallaie S, Sabouri S, Sahebkar A, Oladi M, Mirhosseini N, Shakeri MT, Montaser-Kouhsari S, Omidvar Tehrani S, Ghayour-Mobarhan M, Visvikis-Siest S, Ferns G (2010) Association between angiotensin II type 1 receptor gene polymorphism and metabolic syndrome in a young female Iranian population. Arch Med Res 41(5):343–349. CrossRefPubMedGoogle Scholar
  31. 31.
    Plat AW, Stoffers HE, de Leeuw PW, van Schayck CP, Soomers FL, Kester AD, Aretz K, Kroon AA (2009) The association between arterial stiffness and the angiotensin II type 1 receptor (A1166C) polymorphism is influenced by the use of cardiovascular medication. J Hypertens 27(1):69–75CrossRefGoogle Scholar
  32. 32.
    Yang Y, Tian T, Lu J, He H, Xing K, Tian G (2017) A1166C polymorphism of the angiotensin II type 1 receptor gene contributes to hypertension susceptibility: evidence from a meta-analysis. Acta Cardiol 72(2):205–215. CrossRefPubMedGoogle Scholar
  33. 33.
    Benetos A, Giron A, Joly L, Temmar M, Nzietchueng R, Pannier B, Bean K, Thomas F, Labat C, Lacolley P (2013) Influence of the AGTR1 A1166C genotype on the progression of arterial stiffness: a 16-year longitudinal study. Am J Hypertens 26(12):1421–1427. CrossRefPubMedGoogle Scholar
  34. 34.
    Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277(40):37487–37491. CrossRefPubMedGoogle Scholar
  35. 35.
    Fernandez-Real JM, Castro A, Vazquez G, Casamitjana R, Lopez-Bermejo A, Penarroja G, Ricart W (2004) Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 27(3):739–745CrossRefGoogle Scholar
  36. 36.
    Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96(5):1723–1732CrossRefGoogle Scholar
  37. 37.
    Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105(24):2893–2898CrossRefGoogle Scholar
  38. 38.
    Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103(8):1057–1063CrossRefGoogle Scholar
  39. 39.
    Menzaghi C, Trischitta V, Doria A (2007) Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 56(5):1198–1209. CrossRefPubMedGoogle Scholar
  40. 40.
    Youn JC, Kim C, Park S, Lee SH, Kang SM, Choi D, Son NH, Shin DJ, Jang Y (2013) Adiponectin and progression of arterial stiffness in hypertensive patients. Int J Cardiol 163(3):316–319. CrossRefPubMedGoogle Scholar
  41. 41.
    Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA, Group TS (2011) Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J 161(6):1147–1155 e1141. CrossRefPubMedGoogle Scholar
  42. 42.
    Beltrami-Moreira M, Qi L, Maestri MK, Fuchs FD, Pakter HM, Moreira LB, Gus M, Matte US, Tavares AM, Oliveira MM, Fuchs SC (2015) Association between plasma adiponectin and arteriolar vessel caliber among elderly hypertensive subjects. J Am Soc Hypertens JASH 9(8):620–627 e621. CrossRefPubMedGoogle Scholar
  43. 43.
    Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG (1996) Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 148(1):121–128PubMedPubMedCentralGoogle Scholar
  44. 44.
    Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW, Davidge ST (1999) Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 82(6):1730–1735CrossRefGoogle Scholar
  45. 45.
    Srivastava P, Lone TA, Kapoor R, Mittal RD (2012) Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res 43(2):117–124. CrossRefPubMedGoogle Scholar
  46. 46.
    Zhang LY, Ren KW (2011) Meta-analysis of MMP2-1306T allele as a protective factor in digestive cancer. Arch Med Res 42(3):239–243. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Aikaterini Christodoulou
    • 1
  • Eleni Bagli
    • 1
  • Maria Gazouli
    • 2
  • Marilita M. Moschos
    • 3
  • Georgios Kitsos
    • 1
    Email author
  1. 1.University Eye Clinic of IoanninaIoanninaGreece
  2. 2.Biology Laboratory, Department of MedicineUniversity of AthensAthensGreece
  3. 3.A University Eye Clinic of Athens G. GennimatasAthensGreece

Personalised recommendations